This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Bilirubin is a yellow-orange pigment found in bile, a fluid produced by the liver. It is a product of the breakdown of red blood cells and is eliminated from the body through the stool. Elevated levels of bilirubin in the blood are an indicator of liver disease, gallbladder disease, or a blockage of the bile duct. In the liver, bilirubin is conjugated with glucuronic acid, an enzymatic process that allows the pigment to be water soluble. This allows the bilirubin to be transported through the bile ducts and eliminated in the stool. When this process is disrupted, the bilirubin can be reabsorbed back into the bloodstream, resulting in elevated levels of bilirubin known as jaundice. When a person has jaundice, their skin and eyes may take on a yellowish hue. In newborns, jaundice can be caused by an immature liver, which can lead to a condition known as neonatal jaundice. This is a common condition, and typically resolves on its own within a few weeks. In adults, elevated levels of bilirubin can be an indication of liver disease, such as cirrhosis or hepatitis, gallbladder disease, or a blockage of the bile duct. It is important to diagnose and treat the underlying cause of the elevated bilirubin in order to prevent further damage to the liver or other organs. Treatment options may include lifestyle changes, medications, or surgery, depending on the cause.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States